Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06292598

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients

Status
Recruiting
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Academic / Other
Sex
All
Age
10 Years
Healthy volunteers
Accepted

Summary

Narcolepsy type 1 (NT1) is a rare disease characterized by severe drowsiness, cataplexy, hypnagogic hallucinations, sleep paralysis, poor night sleep, and often obesity. NT1 is caused by irreversible loss of orexin (ORX)/hypocretin neurons in the lateral hypothalamus with decreased ORX levels in the cerebrospinal fluid (CSF). Although the underlying process leading to this destruction remains unclear; an autoimmune origin is suspected. The study authors recently compared the bacterial communities of the fecal microbiota of NT1 patients and control subjects. Initial results demonstrated a difference in overall bacterial community structure in NT1 compared to controls, as assessed by beta diversity, even after adjusting for body mass index (BMI). The Shannon biodiversity index was also correlated with the duration of NT1 disease. However, no association was found between the structure of the microbial community and the clinical characteristics of NT1 patients. In 2022, a second study from the SOMNOBANK cohort on a larger population confirmed these results, showing dysbiosis between NT1 patients and the control population. The altered intestinal microbial diversity supports the important role of the environment in the development and pathogenesis of NT1. Other studies have established a link between dysbiosis, intestinal permeability and inflammation in other neuroimmune pathologies. Currently, no study has focused on these phenomena of bacterial translocation, intestinal permeability and immune activation linked to the microbiota in type 1 narcolepsy patients. The study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation.

Conditions

Interventions

TypeNameDescription
OTHERBlood sampleSample taken to test plasma permeability markers
OTHERStool sampleSample taken to test microbial diversity and composition
OTHERCSF sampleSample taken to test orexin level

Timeline

Start date
2025-03-10
Primary completion
2027-09-01
Completion
2027-09-01
First posted
2024-03-05
Last updated
2025-11-17

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06292598. Inclusion in this directory is not an endorsement.